Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different ...
| BRATOVÁ, Monika, Kristián BRAT, Karolina HURDALKOVA, Magda BARINOVA, Marie DROSSLEROVA, Juraj KULTAN, Matyas WANKE, Leona KOUBKOVA, Jana KREJCI a Martin SVATON. Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity? JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY. NEW ROCHELLE: MARY ANN LIEBERT, INC, 2022, roč. 11, č. 5, s. 451-458. ISSN 2156-5333. Dostupné z: https://dx.doi.org/10.1089/jayao.2021.0069. |
|
Další formáty:
BibTeX
LaTeX
RIS
|
| Základní údaje | |
|---|---|
| Originální název | Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity? |
| Autoři | BRATOVÁ, Monika (203 Česká republika, domácí), Kristián BRAT (703 Slovensko, garant, domácí), Karolina HURDALKOVA (203 Česká republika), Magda BARINOVA (203 Česká republika), Marie DROSSLEROVA (203 Česká republika), Juraj KULTAN, Matyas WANKE (203 Česká republika), Leona KOUBKOVA (203 Česká republika), Jana KREJCI (203 Česká republika) a Martin SVATON (203 Česká republika). |
| Vydání | JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, NEW ROCHELLE, MARY ANN LIEBERT, INC, 2022, 2156-5333. |
| Další údaje | |
|---|---|
| Originální jazyk | angličtina |
| Typ výsledku | Článek v odborném periodiku |
| Obor | 30204 Oncology |
| Stát vydavatele | Spojené státy |
| Utajení | není předmětem státního či obchodního tajemství |
| WWW | URL |
| Impakt faktor | Impact factor: 2.000 |
| Kód RIV | RIV/00216224:14110/22:00125388 |
| Organizační jednotka | Lékařská fakulta |
| Doi | http://dx.doi.org/10.1089/jayao.2021.0069 |
| UT WoS | 000715838900001 |
| Klíčová slova anglicky | non-small cell lung cancer; young patients; younger than the age of 40 years; overall survival; prognosis; mutations |
| Štítky | 14110215, rivok |
| Příznaky | Mezinárodní význam, Recenzováno |
| Změnil | Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 24. 2. 2023 09:52. |
| Anotace |
|---|
| Purpose: Aim was to analyze demographic and tumor characteristics, treatment, and survival of patients with lung cancer younger than 40 years of age (U40) compared to older subgroups (41-70 and >70 years). Methods: We analyzed data of young patients diagnosed and treated in 2011-2019 in five pneumo-oncology centers in Czechia. Standard descriptive statistics, chi-squared test, Fisher exact test, and Kaplan-Meier survival analysis were used. p-Values <0.05 were considered significant. These data were compared with two control subgroups (cohort 1: 41-70 years, cohort 2: >70 years). Results: We identified 66 patients U40, 61 with non-small cell lung cancer (NSCLC)-50.8% men, mean age 34.6 years, 54.1% nonsmokers, daily good performance status, and 82% in stage IV. Adenocarcinomas dominated, endothelial growth factor receptor (EGFR) positivity was less common than in older groups contrary to anaplastic lymphoma kinase (ALK) mutations. Median progression-free survival was 3.7 months (vs. 4.9 and 6.2 months; p = 0.006) and overall survival reached 11.7 months (vs. 22.3 and 27.3 months; p < 0.001). Young patients in stage IV and never-smokers had shorter survival than older patients. Conclusion: Patients with NSCLC U40 had significantly worse prognosis than older patients.
|